Research graph
References from SuperRCA assay of KIT p.D816V mutation load reveals novel correlation to clinical phenotype. Local targets link to admitted publications; unresolved targets remain external evidence.
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
10.1182/blood-2009-02-205237 · 2009 · External reference
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
10.1182/blood.2022015850 · 2022 · External reference
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms
10.1038/s41375-022-01620-2 · 2022 · External reference
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management
10.1002/ajh.26962 · 2023 · External reference
Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay
10.1016/j.jmoldx.2010.10.004 · 2011 · External reference
The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease
10.1111/all.12409 · 2014 · External reference
Digital PCR: a sensitive and precise method for KIT D816V quantification in mastocytosis
10.1373/clinchem.2017.277897 · 2018 · External reference
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis
10.1007/s00277-013-1964-1 · 2014 · External reference
KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes
10.1111/all.15584 · 2023 · External reference
Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis
10.1111/ejh.12128 · 2013 · External reference
Clinical outcomes of adults with systemic mastocytosis: a 15-year multidisciplinary experience
10.3390/cancers14163942 · 2022 · External reference
Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
10.3324/haematol.2019.217950 · 2020 · External reference
KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis
10.1016/j.jaci.2013.02.019 · 2013 · External reference
Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications
10.1038/modpathol.2015.72 · 2015 · External reference
Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM
10.1016/j.jaci.2013.06.020 · 2014 · External reference
Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays
10.1038/s41467-022-31397-y · 2022 · External reference
Improved diagnostic screening and classification of clonal mast cell diseases by ultrasensitive KIT p.D816V detection
10.1182/blood.2025029507 · 2025 · External reference
Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia
10.1182/bloodadvances.2025016726 · 2025 · External reference
Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation
10.1016/j.jaci.2025.10.010 · 2026 · External reference
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management
10.1002/ajh.26962 · ExternalCitation · doi-reference
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis
10.1007/s00277-013-1964-1 · ExternalCitation · doi-reference
KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis
10.1016/j.jaci.2013.02.019 · ExternalCitation · doi-reference
Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM
10.1016/j.jaci.2013.06.020 · ExternalCitation · doi-reference
Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation
10.1016/j.jaci.2025.10.010 · ExternalCitation · doi-reference
Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay
10.1016/j.jmoldx.2010.10.004 · ExternalCitation · doi-reference
Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications
10.1038/modpathol.2015.72 · ExternalCitation · doi-reference
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms
10.1038/s41375-022-01620-2 · ExternalCitation · doi-reference
Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays
10.1038/s41467-022-31397-y · ExternalCitation · doi-reference
The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease
10.1111/all.12409 · ExternalCitation · doi-reference
KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes
10.1111/all.15584 · ExternalCitation · doi-reference
Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis
10.1111/ejh.12128 · ExternalCitation · doi-reference
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
10.1182/blood-2009-02-205237 · ExternalCitation · doi-reference
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
10.1182/blood.2022015850 · ExternalCitation · doi-reference
Improved diagnostic screening and classification of clonal mast cell diseases by ultrasensitive KIT p.D816V detection
10.1182/blood.2025029507 · ExternalCitation · doi-reference
Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia
10.1182/bloodadvances.2025016726 · ExternalCitation · doi-reference
Digital PCR: a sensitive and precise method for KIT D816V quantification in mastocytosis
10.1373/clinchem.2017.277897 · ExternalCitation · doi-reference
Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
10.3324/haematol.2019.217950 · ExternalCitation · doi-reference
Clinical outcomes of adults with systemic mastocytosis: a 15-year multidisciplinary experience
10.3390/cancers14163942 · ExternalCitation · doi-reference
